LOG IN

Overall and progression-free survival of patients with metastatic colorectal cancer: A real‑world prospective, longitudinal cohort study on the continuum of care (PROMETCO)

Data presented at the ESMO Congress 2023

M Koopman,1 R Garcia-Carbonero,2 C Pinto,3 A Mitroshkin,4 G Bodoky,5 L Mineur,6 V Bourgeois,7 M Mare,8 A Ruiz-Casado,9 A Fernandez Montes,10 JM O’Connor,11 A Sullivan,12 E Choucair,13 M Sicaire,13 F Marti Marti,14 JB Bachet15

1. Department of Medical Oncology, University Medical Centre Utrecht, Utrecht University Heidelberglaan 100 3584 CX Utrecht, the Netherlands; 2. Hospital Universitario Doce de Octubre Imas12, UCM, Avenida De Córdoba s/n, 28041 Madrid, Spain; 3. Medical Oncology, Clinical Cancer Centre Azienda USL – IRCCS di Reggio Emilia – Viale Risorgimento, 80 42123 Reggio Emilia, Italy; 4. Klinikum Freudenstadt, Akademisches Lehrkrankenhaus der Universität Tübingen, Karl-von-Hahn Strasse, 120, 72250 Freudenstadt, Germany; 5. Dél-Pesti Centrumkórház Szent László Telephely Albert Flórián út 5–7 1097 Budapest, Hungary; 6. GI and Liver Oncology Unit, Institut of Cancer Sainte Catherine Avignon Provence, France; 7. Boulogne-sur-Mer Hospital Center, Rue Jacques Monod, 62200 Boulogne-sur-Mer, France; 8. Medical Oncology Unit, Mediterranean Institute of Oncology, Viagrande, I-95029 Catania, Italy; 9. Department of Medical Oncology, Hospital Universitario Puerta de Hierro, E-28220 Madrid, Spain; 10. Complexo Hospitalario Universitario de Ourense, Calle Ramon Puga Noguerol, 54, 32005, Orense, Spain; 11. Instituto Alexander Fleming, Buenos Aires, Argentina; 12. Servier Pharmaceuticals, 200 Pier 4 Blvd, Boston, MA 02210, USA; 13. Servier, 35 rue Verdun, 92284 Suresnes, France; 14. The Christie NHS Foundation Trust, 550 Wilmslow Road, Manchester M20 4BX, UK; 15. Sorbonne Université, Service d’hépato-Gastro-Entérologie, Groupe Hospitalier Pitié Salpêtrière, APHP, Paris, France

back to top

PROMETCO: Introduction and aim

  • The primary treatment goal for patients with unresectable mCRC is tumor shrinkage and disease control with preservation or improvement of quality of life1

  • Clinical emphasis lies in avoidance of rapid disease evolution, and prolonging survival1

  • Advances in mCRC treatment have now improved median OS to 30 months in clinical trials1

  • PROMETCO (NCT03935763) is the first international, prospective real-world study to investigate the continuum of care in the mCRC patient population, collecting data on all patients with two disease progressions, regardless of treatment or age

Aims

  • To present preliminary real-world clinical characteristics and treatment patterns of 738 patients with mCRC that has progressed twice on previous treatment

  • To show OS and PFS of the 655/738 patients with mCRC who have completed the study

  • Inclusion criteria: Adult patients with two disease progressions since the first diagnosis of metastatic disease, suitable to receive subsequent treatment, were included

  • Exclusion criteria: Patients enrolled in other clinical trials, receiving treatment for other cancers, or those with reduced mental capacity were excluded

Patient characteristics
(n=738)

Efficacy data on 89% of the population (n=655): PFS and OS

Take-home
messages

mCRC, metastatic colorectal cancer; OS, overall survival; PFS, progression-free survival.
1. Van Cutsem E, et al. Ann Oncol. 2016;27:1386–422.

Patient characteristics in PROMETCO

back to top

Biomolecular status

Age and sex

ECOG PS

Disease characteristics

Treatment/surgery

Efficacy data on 89% of the population

back to top

PFS

OS from mCRC diagnosis

OS from inclusion in PROMETCO

OS from third treatment line

Take-home messages

back to top

 

back to top